Clinical Study on Mannan Peptide Combined with TP Regimen in Treating Patients with Non-small Cell Lung Cancer

Huai-An Yan, Kang Shen, Xin-En Huang

Abstract

**Purpose:** To investigate short-term response rate, quality of life and toxicities of mannan peptide combined with TP regimen in treating patients with non-small cell lung cancer (NSCLC). **Patients and Methods:** Forty one patients with NSCLC were divided into an experimental group treated with TP regimen combined with mannan peptide (21 patients) and a control group treated with TP alone (20 patients). **Results:** Response rates were 61.9% (13/21) for the experimental and 60% (12/20) for the control group (p>0.05). Regarding toxicity, white blood cell decreased more frequently in the control group (65%, 13/20) than in the experimental group (33.3%, 7/21) (p<0.05); nausea and vomiting also occurred more frequently in the control group (55%, 11/20 vs 23.8%, 5/21) (p<0.05). In terms of quality of life, this index was improved by 57.1% (12/21) and 25% (5/20) in experimental and control groups, respectively (p<0.05). **Conclusions:** Response rate of TP after combined with mannan peptide is mildly increased, while this combination alleviates bone marrow suppression as well as nausea and vomiting of TP, and improves quality of life when treating patients with NSCLC. However, this conclusion should be confirmed by randomized clinical trials.

Keywords: Paclitaxel - cisplatin - mannan peptide - non-small cell lung cancer - toxicity

Introduction

It is estimated that 75% of all lung cancers, a leading cause of cancer-related death worldwide, are of non-small cell lung cancer (NSCLC) type (Qin et al., 2013; Wang et al., 2013). Most patients in China present with locally advanced stage III or IV disease. Although current practice for chemotherapy for this cohort of patients includes several newer generation agents such as vinorelbine, gemcitabine, paclitaxel or docetaxel with a platinum agent, no combination has yet emerged as a gold standard (Non-Small Cell Lung Cancer Collaborative Group, 1995; Schiller et al., 2002). Thus, cytotoxic chemotherapy, especially platinum-based doublet chemotherapy continues to be important treatment for advanced NSCLC (Lustberg et al., 2007; Obasaju et al., 2009). However, according to previous report, when oriental patients with advanced NSCLC were treated with platinum-based chemotherapy, the response rate is proximately 19%, and many of these patients would experience disease progression (Schiller et al., 2002; Yao et al., 2009; Li et al., 2011). It is hypothesized that failure of chemotherapeutic treatment could relate to , lower immunological function, multi-drug resistance (MDR) and severe toxicities that discontinue chemotherapy (Gottesman et al, 2002; Illmer et al, 2002). Mannan peptide, is a new immunological enhancer firstly made and in China, and is hypothesized to be associated with none inferior efficacy and low toxicities when combined with chemotherapy. On this background, we retrospectively recruited patients with NSCLC who were treated with chemotherapy alone or combined with mannan peptide, and analyzed the treatment effects and toxicities of Mannan peptide.

Materials and Methods

**General information of patients**

Forty one patients (25 male, 16 female) pathologically or cytologically diagnosed with lung cancer were retrospectively recruited into this study, including 22 patients with squamous and 19 with adenocarcinoma; average age was 58 years; KPS score> 70 and expected survival time > 6 months. All patients were divided into experimental (21 patients) or control group (20 patients). All patients had imaging examination including CT or MRI before and after treatment.

**Treatment**

Experimental group was treated with TP regimen combined with mannan peptide (Sinopharma A-Think Pharmaceutical Co., Ltd –mannan peptide for injection): paclitaxel 85 mg/m², intravenous infused (iv.) on d1 and d

---

1Tumor Department of Siyang People’s Hospital, Suqian. 2Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China. *Equal contributors *For correspondence: huangxinen06@aliyun.com
Table 1. Short-term Responsiveness (CR+PR)

<table>
<thead>
<tr>
<th>Number of patients</th>
<th>CR</th>
<th>PR</th>
<th>SD</th>
<th>PD</th>
<th>Response rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Experimental group</td>
<td>21</td>
<td>4</td>
<td>9</td>
<td>6</td>
<td>61.9</td>
</tr>
<tr>
<td>Control group</td>
<td>20</td>
<td>3</td>
<td>9</td>
<td>5</td>
<td>60</td>
</tr>
</tbody>
</table>

Table 2. Incidence of Toxicities in Two Groups (0 - IV degrees)

<table>
<thead>
<tr>
<th>Toxicities</th>
<th>0</th>
<th>I</th>
<th>II</th>
<th>III</th>
<th>IV</th>
<th>Incidence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nausea and vomiting</td>
<td>16</td>
<td>3</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>23.8</td>
</tr>
<tr>
<td>Control group</td>
<td>9</td>
<td>4</td>
<td>2</td>
<td>4</td>
<td>1</td>
<td>55</td>
</tr>
<tr>
<td>Leukocytopenia</td>
<td>14</td>
<td>4</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>33.3</td>
</tr>
<tr>
<td>Control group</td>
<td>7</td>
<td>5</td>
<td>3</td>
<td>2</td>
<td>3</td>
<td>65</td>
</tr>
</tbody>
</table>

Table 3. Changes of quality of survival in two groups

<table>
<thead>
<tr>
<th>Improved</th>
<th>Stabilized</th>
<th>Decreased</th>
<th>Responsive rate %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Experimental group</td>
<td>5</td>
<td>7</td>
<td>9</td>
</tr>
<tr>
<td>Control group</td>
<td>2</td>
<td>3</td>
<td>15</td>
</tr>
</tbody>
</table>

Toxicities

Nausea/vomiting and leukocytopenia occurred in most of patients. After symptomatic treatment, these toxicities were alleviated, and no influence on further treatment. However, significantly different toxicities were observed between two groups (p<0.05), as shown in Table 2.

Quality of survival

Quality of life in experimental group was improved by 23.8%, stabilized by 33.3% and decreased by 42.9%; in control group was improved by 10%, stabilized by 15% and decreased by 75%, with statistically significant difference between two groups (p<0.05), as shown in Table 3.

Discussion

At present, chemotherapy is one of the main methods to treat middle-late staged NSCLC, and the treatment goal is to improve quality of life and prolong survival time. Paclitaxel acts in G2 and M-stage cell cycle, induces and promotes polymerization of tubulin, prevents depolymerization, stabilizes microtubules, inhibits the formation of spindle and spindle fiber and thus stops proliferation of tumor cell. Paclitaxel combined with cisplatin is associated with higher response rate. However, adverse reactions will increase when these two chemotherapeutic agents combined, including leukocytopenia, nausea and vomiting so that it was difficult for patients to tolerate. Therefore, how to find a regimen that will strengthen the curative effect and improve immunologic function of patients and reduce adverse reactions is an important research direction at present. Mannan peptide is a new immunologic enhancer. Previous studies suggested that mannan peptide is linked with functions to activate phagocyte, NK cell and subgroup of T, B cells and induce unripe interferon and interleukin and cause DNA rupture of tumor cell and viruses and apoptosis of cell (He et al., 2007). It is suggested that mannan peptide is able to enhance phagocytes of mononuclear phagocyte system, activate macrophages and lymphocyte, improve curative effect of chemotherapy, reduce side effects and improve quality of life (He et al., 2007). In this study, mannan peptide combined with chemotherapy was compared with single chemotherapy regarding response rate, adverse effects as well as change of patient quality of life. Our results showed that response rate of mannan peptide group be slightly higher than that in group with chemotherapy alone; the incidence of bone marrow suppression and gastrointestinal side reactions was significantly decreased, with statistically significant difference. The quality of life in experimental group was significantly improved, with statistically significant difference between two groups.

In conclusion, response rate of TP after combined...
with mannan peptide is mildly increased, while this combination alleviates bone marrow suppression as well as nausea and vomiting of TP, and improves quality of life when treating patients with NSCLC. However, this conclusion should be confirmed by randomized clinical trials.

Acknowledgements

Dr. Xin-En Huang is supported in part by a grant from Jiangsu Provincial Administration of Chinese Medicine (LZ11091), and in part from a special research fund of Organization Department of Jiangsu Provincial Party Committee, Talent Work Leading Group of Jiangsu Province (333 High-level Talents Training Project).

References


Huai-An Yan et al


